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Aim: The study aimed to determine a prognostic value of primary tumor volume mea-
sured on the basis of integrated positron emission tomography–computerized tomography
(PET–CT) in terms of mediastinal nodal metastases (N2) prediction in non-small-cell lung
cancer (NSCLC) patients with PET–CT N2 negative lymph nodes.
Methods: The records of 70 potentially operable NSCLC patients treated with surgical resec-
tion were analyzed. All patients underwent diagnostic, preoperative PET–CT, which was the
basis for tumor volume calculations as well as the evaluation of N2 nodes status. The logis-
tic  regression analysis was employed to determine correlation between mediastinal nodal
involvement and volume of primary tumor (izoSUV2.5 volume), that is the volume of pri-
mary  tumor inside SUV 2.5 line, tumor histology, location (peripheral vs. central), hilar node
status.
Results: A statistically signiﬁcant correlation between mediastinal node involvement andizoSUV2.5 volume, tumor histology, locations peripheral vs. central and hilar node status
was  found. The risk of mediastinal lymph node metastasis is 24% for tumor volume of
100  cm3 and increases up to 40% for tumor volume of 360 cm3. An increase of tumor volume
by  1 cm3 increases the risk of lymph node disease by 0.3%. Tumor histology adenocarcinoma
vs.  squamous cell carcinoma increases the risk of mediastinal lymph node involvement by195%, location central vs. peripheral by 68% and hilar node involvement by 166%.
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Conclusions: The study demonstrates that izoSUV2.5 volume of primary tumor may be con-
sidered as a prognostic factor in NSCLC patients, since it strongly correlates with mediastinal
lymph node pathological status. This correlation is modiﬁed by primary tumor location,
histology and hilar node involvement.
©  2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
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b.  Background
he most absorbing issue in modern oncology of non-small-
ell lung cancer (NSCLC) is the implementation of integrated
ositron emission tomography–computerized tomography
PET–CT) to the diagnostic process. PET–CT offers superior
ensitivity and speciﬁcity compared to CT or PET alone and
ay improve staging accuracy. Mediastinal lymph nodes
tatus in NSCLC patients has important therapeutic and
rognostic implications. The current consensus is that a posi-
ive mediastinal nodal uptake on PET–CT should be veriﬁed
istologically by mediastinoscopy or transbronchial needle
spiration while negative uptake in the mediastinum should
roceed to resection. A signiﬁcant proportion of PET–CT medi-
stinum negative cases will turn out to be positive following
esection. There is a high probability that tumor volume has
reat value in predicting lymph node involvement, a feature,
hich decreases 5-year survival by 30–40%.
.1.  Aim
he study aimed to determine a prognostic value of primary
umor volume measured on the basis of PET–CT (izoSUV2.5
olume) in terms of mediastinal nodal metastases prediction
n NSCLC patients.
.  Material  and  methods
.1.  Selection  of  patients
etween September 2008 and December 2009, a total num-
er of 70 consecutive potentially operable NSCLC patients
ere treated with a curative intent. From the total number
f 425 evaluated by PET–CT newly diagnosed NSCLC patients,
55 (83%) presented a more  advanced disease. Diagnostic
ET–CT performed in all 70 did not depict mediastinal lymph
ode involvement (PET–CT N2 negative patients). All these
atients were treated radically, 62 of them underwent anatom-
cal resections and 8 of them wedge resections. As regards
natomical resections, 8 pneumonectomies – all left-sided,
 inferior bilobectomies and 48 lobectomies (22 right-sided
nd 26 left-sided) were performed. All patients underwent a
ystematic lymph node dissection and were then examined
athologically. The patients were given antibiotics and anti-
hrombotic prophylaxis perioperatively.
The mean age of patients was 63 years, ranging from 22
o 78; 44 of them were male (62.9%) and 26 female (37.1%).
he clinical staging was based on the following criteria: gen-
ral clinical examination, biopsy, routine blood cell counts,
lood chemistry proﬁle, chest X-ray and chest CT, abdominalrights reserved.
ultrasonography, bronchoscopy and pulmonary function test.
The pathological diagnosis of most patients was squamous
cell carcinoma in 35 patients (50%), adenocarcinoma in 26
(37%), large cell carcinoma in 8 (12%) and mucoepidermoid
carcinoma in 1 (2%) case. The grading was: G1 in 1, G2 in 28,
G3 in 17 and unknown in 24 cases. Primary tumor stage was
T1 in 23, T2 in 35, T3 in 12 patients. There were 33 PET N1
positive cases and 37 negative ones. Peripheral location was
determined in 55 patients while central in 15.
2.2.  Image  analysis
All patients underwent PET–CT examination as a routine pro-
cedure before the decision of surgery. The whole body scan
(Biograph 6 and Biograph 16, Siemens, Erlangen, Germany)
was performed for the evaluation of primary tumor, lymph
node involvement, distant metastases and tumor volume
computations. All patients were fasted for at least 6 h before
the examination. Blood glucose levels were determined before
injection of 5–7 MBq/kg [18F]ﬂuorodeoxyglucose (FDG). FDG
was produced in our own laboratory. Sixty minutes after
administration of FDG, PET–CT scans were obtained from the
skull base to the ¼ upper level of the hips. Diagnostic CT was
done in 6–7 beds, 2 min  each, of PET imagining performed
according to the height of the patient. Images were recon-
structed using 3D iterative reconstruction.1,2
Whole body images in DICOM formats were sent online via
PACS system (Siemens, Erlangen, Germany) to the external
beam radiotherapy treatment planning system. Tumor area
was identiﬁed and delineated on each PET–CT scan by the
oncologist with the assistance of a nuclear medicine special-
ist, who was unaware of clinical and pathological ﬁndings.
IzoSUV2.5 volumes, that is the volume of primary tumor inside
SUV 2.5 line, were calculated automatically using the True D
radiotherapy treatment planning system (Siemens, Erlangen,
Germany; Fig. 1).
Lymph nodes greater than 10 mm in the short axis and
SUV > 2.5 were interpreted as metastatic.
2.3.  Statistical  analysis
Pathologically conﬁrmed mediastinal lymph node involve-
ment was the endpoint of the study. The correlation between
mediastinal nodal metastasis occurrence (pathologically
conﬁrmed) and such parameters as: izoSUV2.5 volume, SUV
max, tumor pathological type and grade, primary tumor stage,
diameter and location (peripheral vs. central), hilar node sta-
tus (PET N1) as well as patient’s age and sex were determined
using the univariate logistic regression. Correlation between
statistically signiﬁcant variables and lymph node involve-
ment were assessed using the multivariate logistic regression
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Fig. 1 – PET–CT scan – delineated tumor (white line) is
visible as a high-signal mass comprising the peripheral
part of the lung. The calculated izoSUV2.5 volume of
primary tumor, without N1 mass, is shown.
Fig. 2 – Tumor volume parameters categorized into two
groups according to the status of mediastinal lymph nodes,
pN2 positive (metastatic) lymph nodes, pN2 negative (free)
risk of mediastinal lymph involvement by 68%. PET–CT N1
metastatic feature increased the risk of mediastinal lymph
involvement by 166%.analysis. Odds ratio (OR) and its 95% conﬁdential interval (CI)
were estimated. Additionally, a sigmoid risk curve was drawn
and its coefﬁcient was obtained. The maximum likelihood
method enabled drawing the best adjusted risk curve and
assessing a statistical signiﬁcance of the adjustment. A value
of p = 0.05 was accepted as statistically signiﬁcant. Tumor
volumes were computed for both distinguished patient
groups, with and without mediastinal lymph node disease,
and compared with the t-Student test. All the calculations
were made using the Statistica’99 software.3
3. Results
Mediastinal nodal metastases (pN2+) were found in 16 (23%)
out of 70 operated patients. Thus, 54 (77%) out of 70 patients
represented a negative mediastinal lymph node status (pN2−).
In the whole group of patients, approximately 9.1 lymph nodes
(standard deviation (SD) 5.3; range 1–27) were removed. In
groups (pN2+) and (pN2−), approximately 10 (SD 5.8; range
1–23) and 8.8 (SD 5.1; range 1–27) lymph nodes were removed,
respectively. In the mediastinal lymph node involvement
group a vessel embolism of neoplasm cells in 5 patients and
an extracapsular inﬁltration in 4 others were observed.
The mean izoSUV2.5 volume was 45 cm3, SD 99 cm3. In
patients with nodal metastases izoSUV2.5 volumes were sig-
niﬁcantly higher compared to those in patients with no nodal
involvement: 65.9 cm3, SD 113.5 cm3 vs. 40.9 cm3, SD 91.3 cm3;
t test p = 0.003 (Fig. 2).
In the univariate logistic regression analysis the statis-
tical signiﬁcance was found for six parameters: SUV max,
izoSUV2.5 volume, tumor histology type, stage and location
peripheral vs. central and hilar node status (Table 1).lymph nodes.
In the multivariate logistic regression analysis the statisti-
cal signiﬁcance was found for four parameters only, including
izoSUV2.5 volume, tumor histology type, location peripheral
vs. central, hilar node status (Table 2).
Fig. 3 represents the risk of mediastinal lymph node
involvement as a function of izoSUV2.5 volume deﬁned on
the basis of PET–CT images. The probability of mediastinal
lymph node metastasis is 24% for tumor volume of 100 cm3
and increases up to 40% for tumor volume of 360 cm3. The
logistic regression analysis showed that each 1 cm3 of tumor
volume increases the risk of mediastinal lymph node involve-
ment by 0.3%, with odds ratio of 1.0034. The model predicts a
23% risk for the “0” cm3 izoSUV2.5 volume (invisible tumor).
Tumor histology adenocarcinoma vs. squamous cell carci-
noma increased the risk of mediastinal lymph involvement
by 195%. Tumor location central vs. peripheral increased theFig. 3 – Relationship between the risk of mediastinal nodal
involvement and tumor volume.
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Table 1 – The risk of mediastinal lymph node involvement, the univariate logistic regression analysis.
Odds ratio Conﬁdence interval p-Value
−95% +95%
izoSUV2.5 volume 1.0022 1.0006 1004 <0.001
Location peripheral vs. central 1.45 1.02 2.22 0.04
HP adeno vs. squamous 2.1 1.6 2.9 <0.001
N1 PET vs. N0 PET 2.38 1.6 3.4 <0.001
T stage 1.31 1.00 1.73 0.04
SUV max 1.05 1.00 1.12 0.02
Table 2 – The multivariate logistic regression analysis, the risk of mediastinal lymph node involvement as a function of
independent variable.
Odds ratio Conﬁdence interval p-Value
−95% +95%
izoSUV2.5 volume 1.0034 1.0015 1.0053 0.0004
Location peripheral vs. central 1.68 1.02 2.77 0.04
HP adeno vs. squamous 2.95 2.02 4.30 <0.001
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Fig. 4 presents the risk of mediastinal lymph node involve-
ent as a function of izoSUV2.5 volume and tumor histology.
.  Discussion
ccording to expectations, a statistical signiﬁcance was
emonstrated between the izoSUV2.5 volume and mediastinal
ymph node involvement risks, assessed pathologically.
Asamura4 found that among patients with resected periph-
ral NSCLC, the prevalence of lymph node metastases
ncreased from 19.5% in tumors 2.0 cm or smaller to 32.5% in
umors 2 to 3.0 cm in diameter. Like Stiles,5 he highlights that
n the group of primary tumors 0–2 cm vs. >2 cm the risk rises
.4 times.
6Lee discovered a growing risk of micrometastasis: 4.8%,
.5%, 6.3%, 57% for primary tumors 0–2, 2.1–4, 4.1–6 and >6 cm
n diameter, respectively.
ig. 4 – Relationship between the risk of mediastinal nodal
nvolvement and tumor volume according to pathological
ype, adenocarcinoma – dashed, squamous – dotted line.1.76 4.02 <0.001
0.5
0.2
In our result, the 23% incidence of occult pN2 metasta-
sis approached that given by Melek 20.3%,7 Periguad8 19.6%,
Al-Sarraf9 16%, Tournoy10 16%, Gomez-Caro11 14.4%, who
recruited from a similar group of patients. At the same time,
however, there is much concern about our cutting point
(SUV2.5 and 1 cm in short axis) which could be suggested as
being too liberal.
Current evidence conﬁrms that there is a connection
between adenocarcinoma and an increased risk of under-
staging: our results support this thesis. Such outcomes are
also presented by Gomez-Caro,11 Melek,7 Lee,6 Carnochan,12
Bille,13 Stiles.5
We  agree with Gomez-Caro11 and Cardia14 that such vari-
ables as side and age are not inﬂuential. But in contrast to us,
they do not indicate the signiﬁcance of tumor size, but gender
role.
The feature of primary tumor, which is conversely assessed
as the risk factor of incidence of occult N2 disease, is SUV max.
Lee6 concluded that tumors with occult N2 metastases had a
signiﬁcantly higher median SUV max  compared with those
without N2 disease: 6.0 g/mL vs. 3.6 g/mL. And the prevalence
of occult N2 disease increased signiﬁcantly from 1.9% to 10.5%
when SUV max  of the primary tumor exceeded 4.0 g/mL.
Downey15 also noted that uptake in patients with patho-
logical nodal involvement was higher than in those who  were
N0 too. The mean SUV in N0 patients was 8.9 ± 6.3 and the
mean SUV in N1–2 patients was 13.6 ± 6.9. In this observa-
tion, tumor volume compound is needed to assess the mean
SUV of primary tumor. In our group of patients we  did not
found statistically signiﬁcant differences between the SUV
max  of primary tumor in both subgroups, pN2  negative vs.
pN2 positive, in the multivariate logistic regression analysis.
The statistical signiﬁcance of the SUV max  is disappearing for
the beneﬁt of izoSUV2.5 volume, which better explains the risk
of mediastinal nodal metastases.The coexistence of two independent variables, i.e. the size
of primary tumor and histology, is suggested by Casali16 in
the assessment of the biological aggressiveness of lung cancer
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and, as a result, prognosis. These two factors are relevant in
our material as well.
Kanzaki17 demonstrated that adenocarcinoma, tumors
located in the upper or middle lobe, tumor size >3 cm,  and
SUVmax of primary tumor >4.0 g/mL are risk factors for occult
MLN  metastasis.
The limit of resolution for the PET–CT system can explain
the majority of false negative cases.8 The other cause could be
a central tumor location, which obscures adjacent lymph node
invasion.9 On the other hand, the presence of air in surround-
ing structures (lungs) makes ultrasound visualization of the
lymph nodes impossible in opposition to e.g. head and neck
cancer patients.18,19
Our principal ﬁnding is the correlation between tumor vol-
ume and lymph node status. The frequency of lymph node
metastases was signiﬁcantly higher in patients with larger
tumor volumes compared with those with smaller ones. A
change of tumor volume by 1 cm3 highly alter the risk of medi-
astinal nodal involvement by 0.3%. This relation is modiﬁed
as well by histology, tumor locations and hilar nodes involve-
ment.
It is a well known fact, however, that, apart from dis-
tant metastases, positive mediastinal lymph nodes are the
most signiﬁcant prognostic factors for recurrence and death
in NSCLC patients.
We  realize that a relatively small group of patients that
might have inﬂuenced the statistical power of the analysis is
a meaningful limitation of our results. However, the impor-
tant fact is that our model allowed us to distinguish a group of
patients whose risk of lymph node disease is low, for example
less than 25% or 33% (predicted for the volume of 48 cm3 and
210 cm3, respectively). A more  pronounced risk, for example
greater than 50% (predicted in our model for 540 cm3) could
suggest an alteration in treatment strategy, for example an
exclusion of surgery. Unquestionably, further studies, with a
higher number of patients, are required to conﬁrm the pre-
sented preliminary results. So far, our retrospective research,
restricted to one hospital, does not allow us to suggest any
strong recommendations on changing the treatment protocol,
depending on tumor volume and thus the risk of mediasti-
nal node metastasis. This is only a monograph to discuss that
topic as well as the cost-effectiveness aspect.20
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